Sentence examples for trial boundaries from inspiring English sources

Trial boundaries are rationalised to four values of seasonal performance providing the opportunity to reassess the UK EST heat pump trial results and identify two boundary conditions directly relevant to the interpretation of the Renewable Energy Sources Directive.

The activists said the trial, at Rothamsted Research in Harpenden, Hertforshire, is a threat to agriculture because pollen from the GM wheat could contaminate non-GM plants outside the trial boundary.

In clinical trials boundaries for early stopping after an interim analysis may be incorporated.

A power analysis was conducted using simulations of continuously monitored, trial-stopping boundaries to determine the accrual buffer needed to suspend a trial after an adverse event (7).

Since there was no significant trend in the effects by distance from the trial area boundary (Table 2), extrapolations assumed that effects were consistent throughout the affected areas.

We used previously published methods [10], [11] to investigate whether the effect of culling varied with distance from the trial area boundary.

For the period comprising the during-trial period and the first 30 months of the post-trial period (when beneficial effects were detectable), there was no significant linear effect of distance from the trial area boundary on the magnitude of the beneficial effect (Table 2).

The sequential analysis confirmed the primary meta-analysis when using the traditional 5% level of statistical significance (figure 3), but not after adjusting for multiple testing (the trial monitoring boundary was not crossed).

We've done analyses to show that there is no cost of boundary switching on either accuracy or reaction time (Author response image 4); no evidence of a win-stay, lost-shift strategy (Author response image 5); or effect of previous trial speed, boundary or outcome on the current trial (Author response image 6).

The cumulative z curve crosses neither the traditional boundary nor the trial sequential monitoring boundary but does cross the futility boundary, suggesting firm evidence for a lack of even an average 7.5% relative risk increase (upper confidence limit 11%) of myocardial infarction with angiotensin receptor blockers (see fig B1 in appendix 3 on bmj.com).

Meta-analyses not reaching information size are analyzed with trial sequential monitoring boundaries analogous to interim monitoring boundaries in a single trial.